[시장보고서]표적 단백질 분해(TPD) 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

표적 단백질 분해(TPD) 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Targeted Protein Degradation Market Size, Share & Trends Analysis Report By Type, By Application, By End Use, By Region, And Segment Forecasts, 2026 - 2033

상품코드 : 1941452

리서치사 : Grand View Research

발행일 : 2026년 01월

페이지 정보 : 영문 120 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,981,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,491,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 13,510,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

표적 단백질 분해(TPD) 시장의 요약

세계의 표적 단백질 분해(TPD) 시장 규모는 2025년에 6억 9,930만 달러로 추정되며, 2033년까지 32억 5,740만 달러에 달할 것으로 예측됩니다.

2026-2033년 연평균 복합 성장률(CAGR) 20.75%를 나타낼 것으로 예측됩니다. 암, 신경퇴행성 질환 등 만성질환의 지속적인 유병률 증가, 생활양식의 변화, 의료비 증가가 시장 성장을 가속화하고 있습니다.

이러한 질환의 높은 유병률은 새로운 치료법에 대한 강력한 수요를 창출하여 시장 성장을 주도하고 있습니다. 이 분야의 연구개발 활동의 확대는 큰 성장 기회를 제공합니다. 예를 들어 2023년 12월 오스트리아 과학기금(FWF)은 표적 단백질 분해(TPD)에 대한 특별 연구 프로그램(SFB)에 대해 4년간의 2차 자금 지원을 승인했습니다. 표적 단백질 분해(TPD) 관련 SFB는 특정 단백질을 표적으로 삼아 세포 내에서 분해시키는 방법을 이해하고 개발하는 데 초점을 맞춘 연구 구상입니다. 이 프로그램은 최근 신약개발 및 치료 중재에 대한 적용 가능성으로 인해 최근 큰 주목을 받고 있는 표적단백질분해(TPD) 분야의 발전을 목표로 하고 있습니다.

특히 FDA와 EMA와 같은 기관의 승인 절차의 효율화 등 지원적인 규제 환경이 표적 단백질 분해(TPD) 기반 치료법의 보급을 가속화하는 데 중요한 역할을 해왔습니다. 기반 기술의 급속한 발전이 표적 단백질 분해(TPD) 산업을 주도하고 있습니다. 프로테오리시스 표적 키메라(PROTAC), 분자접착제, 리소좀 표적 키메라(LYTAC)와 같은 혁신적인 기법의 개발로 질병을 유발하는 단백질을 선택적으로 제거하는 표적단백질분해(TPD)의 능력이 확대되었습니다. 이러한 기술적 혁신은 기존에 치료 대상이 아니었던 단백질을 표적으로 하는 새로운 길을 열어 표적 단백질 분해(TPD) 산업의 성장을 촉진하고 있습니다.

표적 단백질 분해(TPD)가 기존에 치료하기 어려웠던 표적에 대한 치료 가능성으로 그 가치가 널리 인식되고 있는 것이 이 산업의 주요 촉진제입니다. 기존 치료법으로는 조절이 어려운 단백질에 대한 대응이 어려운 경우가 많았는데, PROTAC(프로테오리시스 표적 키메라)과 같은 기술은 질병 관련 단백질의 분해를 촉진하여 유망한 해결책을 제시합니다. 이 방법은 암, 신경 퇴행성 질환 등의 치료에 매우 유망한 결과를 보여주고 있으며, 이 분야의 연구개발이 급증하고 있습니다. 미국 국립보건원(NIH)은 최근 PROTAC을 주요 신약개발 기술로 주목하고 있습니다. 전임상 및 초기 임상시험의 성공 사례가 증가함에 따라 제약사와 생명공학 기업은 치료 전략의 변화 가능성을 인식하고 표적 단백질 분해(TPD)를 자사 파이프라인에 통합하는 것을 추진하고 있습니다.

영문목차

Targeted Protein Degradation Market Summary

The global targeted protein degradation market size was estimated at USD 699.3 million in 2025 and is projected to reach USD 3,257.4 million by 2033, growing at a CAGR of 20.75% from 2026 to 2033. The constantly growing frequency of chronic disease conditions such as cancer and neurodegenerative diseases, along with changing lifestyles and increasing healthcare spending, is accelerating the market growth.

The high prevalence of these diseases creates a strong demand for novel treatment options, driving market growth. The expanding number of research and development activities in this field provides significant market growth opportunities. For instance, in December 2023, the Austrian Science Fund (FWF) approved the Special Research Program (SFB) in Targeted Protein Degradation for a second funding period of another four years. The SFB in targeted protein degradation is a research initiative focusing on understanding and developing methods to target specific proteins for cell degradation. This program aims to advance the field of targeted protein degradation, which has gained significant attention in recent years due to its potential applications in drug discovery and therapeutic interventions.

The supportive regulatory environment, particularly the streamlined approval processes by agencies such as the FDA and EMA, has played a crucial role in accelerating the adoption of TPD-based therapies. Rapid advancements in the underlying technologies drive the targeted protein degradation industry. The development of innovative approaches, such as proteolysis-targeting chimeras (PROTACs), molecular glues, and lysosome-targeting chimeras (LYTACs), has expanded TPD's capabilities to eliminate disease-causing proteins selectively. These technological breakthroughs have opened up new avenues for targeting previously undruggable proteins, driving the growth of the targeted protein degradation industry.

The increasing recognition of the therapeutic potential of targeted protein degradation in addressing previously undruggable targets is a key driver for the targeted protein degradation industry. Traditional approaches often struggle with proteins that are difficult to modulate, but technologies such as PROTACs (proteolysis-targeting chimeras) provide a favorable solution by promoting the degradation of disease-causing proteins. This method has shown considerable promise in treating conditions such as cancer and neurodegenerative disorders, sparking a surge in research and investment in this area. The National Institute of Health highlights PROTACs as a leading drug development technology in recent years. The increasing success in preclinical and early-phase clinical trials drives pharmaceutical and biotech companies to integrate targeted protein degradation into their pipelines, recognizing its potential to transform therapeutic strategies.

Global Targeted Protein Degradation Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global targeted protein degradation market report based on type, application, end use, and region:

Type Outlook (Revenue, USD Million, 2021 - 2033)
PROTAC
Molecular Glues
LYTACs
Others
Application Outlook (Revenue, USD Million, 2021 - 2033)
Drug Discovery
Therapy Development
- Cancer
- Neurology
- Infectious Diseases
- Cardiovascular Diseases
- Others
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Hospitals & Clinical Laboratories
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
Latin America
- Brazil
- Argentina
Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Market Definitions
- 1.2.1. Type Segment
- 1.2.2. Application Segment
- 1.2.3. End Use Segment
1.3. Information analysis
- 1.3.1. Market formulation & data visualization
1.4. Data validation & publishing
1.5. Information Procurement
- 1.5.1. Primary Research
1.6. Information or Data Analysis
1.7. Market Formulation & Validation
1.8. Market Model
1.9. Total Market: CAGR Calculation
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Targeted Protein Degradation Market Variables & Trends

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
- 3.2.1. Market driver analysis
  - 3.2.1.1. Growing frequency of chronic diseases
  - 3.2.1.2. Research and development activities
  - 3.2.1.3. Increasing recognition of the therapeutic potential of targeted protein degradation
- 3.2.2. Market restraint analysis
  - 3.2.2.1. Stringent regulations associated with approvals for novel TPD based therapies
3.3. Targeted Protein Degradation Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.2. PESTEL Analysis

Chapter 4. Targeted Protein Degradation Market: Type Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Global Targeted Protein Degradation Market Type Movement Analysis
4.3. Global Targeted Protein Degradation Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
4.4. PROTAC
- 4.4.1. PROTAC market estimates and forecasts 2021 to 2033 (USD Million)
4.5. Molecular Glues
- 4.5.1. Molecular Glues market estimates and forecasts 2021 to 2033 (USD Million)
4.6. LYTACs
- 4.6.1. LYTACs market estimates and forecasts 2021 to 2033 (USD Million)
4.7. Others
- 4.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Targeted Protein Degradation Market: Application Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Global Targeted Protein Degradation Market Application Movement Analysis
5.3. Global Targeted Protein Degradation Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
5.4. Drug Discovery
- 5.4.1. Drug Discovery market estimates and forecasts 2021 to 2033 (USD Million)
5.5. Therapy Development
- 5.5.1. Therapy Development market estimates and forecasts 2021 to 2033 (USD Million)
- 5.5.2. Cancer
  - 5.5.2.1. Cancer market estimates and forecasts 2021 to 2033 (USD Million)
- 5.5.3. Neurology
  - 5.5.3.1. Neurology market estimates and forecasts 2021 to 2033 (USD Million)
- 5.5.4. Infectious Diseases
  - 5.5.4.1. Infectious Diseases market estimates and forecasts 2021 to 2033 (USD Million)
- 5.5.5. Cardiovascular Diseases
  - 5.5.5.1. Cardiovascular Diseases market estimates and forecasts 2021 to 2033 (USD Million)
- 5.5.6. Others
  - 5.5.6.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Targeted Protein Degradation Market: End Use Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Global Targeted Protein Degradation Market End Use Movement Analysis
6.3. Global Targeted Protein Degradation Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
6.4. Pharmaceutical & Biotechnology Companies
- 6.4.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2021 to 2033 (USD Million)
6.5. Academic & Research Institutes
- 6.5.1. Academic & Research Institutes market estimates and forecasts 2021 to 2033 (USD Million)
6.6. Hospitals & Clinical Laboratories
- 6.6.1. Hospitals & Clinical Laboratories market estimates and forecasts 2021 to 2033 (USD Million)
6.7. Others
- 6.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Targeted Protein Degradation Market: Regional Estimates & Trend Analysis

7.1. Regional Market Share Analysis, 2025 & 2033
7.2. Regional Market Dashboard
7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
7.4. North America
- 7.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 7.4.2. U.S.
  - 7.4.2.1. Key country dynamics
  - 7.4.2.2. Competitive scenario
  - 7.4.2.3. Regulatory framework
  - 7.4.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
- 7.4.3. Canada
  - 7.4.3.1. Key country dynamics
  - 7.4.3.2. Competitive scenario
  - 7.4.3.3. Regulatory framework
  - 7.4.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
- 7.4.4. Mexico
  - 7.4.4.1. Key country dynamics
  - 7.4.4.2. Competitive scenario
  - 7.4.4.3. Regulatory framework
  - 7.4.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
7.5. Europe
- 7.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.2. UK
  - 7.5.2.1. Key country dynamics
  - 7.5.2.2. Competitive scenario
  - 7.5.2.3. Regulatory framework
  - 7.5.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.3. Germany
  - 7.5.3.1. Key country dynamics
  - 7.5.3.2. Competitive scenario
  - 7.5.3.3. Regulatory framework
  - 7.5.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.4. France
  - 7.5.4.1. Key country dynamics
  - 7.5.4.2. Competitive scenario
  - 7.5.4.3. Regulatory framework
  - 7.5.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.5. Italy
  - 7.5.5.1. Key country dynamics
  - 7.5.5.2. Competitive scenario
  - 7.5.5.3. Regulatory framework
  - 7.5.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.6. Spain
  - 7.5.6.1. Key country dynamics
  - 7.5.6.2. Competitive scenario
  - 7.5.6.3. Regulatory framework
  - 7.5.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.7. Norway
  - 7.5.7.1. Key country dynamics
  - 7.5.7.2. Competitive scenario
  - 7.5.7.3. Regulatory framework
  - 7.5.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.8. Sweden
  - 7.5.8.1. Key country dynamics
  - 7.5.8.2. Competitive scenario
  - 7.5.8.3. Regulatory framework
  - 7.5.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.9. Denmark
  - 7.5.9.1. Key country dynamics
  - 7.5.9.2. Competitive scenario
  - 7.5.9.3. Regulatory framework
  - 7.5.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
7.6. Asia Pacific
- 7.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.2. Japan
  - 7.6.2.1. Key country dynamics
  - 7.6.2.2. Competitive scenario
  - 7.6.2.3. Regulatory framework
  - 7.6.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.3. China
  - 7.6.3.1. Key country dynamics
  - 7.6.3.2. Competitive scenario
  - 7.6.3.3. Regulatory framework
  - 7.6.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.4. India
  - 7.6.4.1. Key country dynamics
  - 7.6.4.2. Competitive scenario
  - 7.6.4.3. Regulatory framework
  - 7.6.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.5. Australia
  - 7.6.5.1. Key country dynamics
  - 7.6.5.2. Competitive scenario
  - 7.6.5.3. Regulatory framework
  - 7.6.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.6. South Korea
  - 7.6.6.1. Key country dynamics
  - 7.6.6.2. Competitive scenario
  - 7.6.6.3. Regulatory framework
  - 7.6.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.7. Thailand
  - 7.6.7.1. Key country dynamics
  - 7.6.7.2. Competitive scenario
  - 7.6.7.3. Regulatory framework
  - 7.6.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
7.7. Latin America
- 7.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 7.7.2. Brazil
  - 7.7.2.1. Key country dynamics
  - 7.7.2.2. Competitive scenario
  - 7.7.2.3. Regulatory framework
  - 7.7.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
- 7.7.3. Argentina
  - 7.7.3.1. Key country dynamics
  - 7.7.3.2. Competitive scenario
  - 7.7.3.3. Regulatory framework
  - 7.7.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
7.8. Middle East and Africa
- 7.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 7.8.2. South Africa
  - 7.8.2.1. Key country dynamics
  - 7.8.2.2. Competitive scenario
  - 7.8.2.3. Regulatory framework
  - 7.8.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
- 7.8.3. Saudi Arabia
  - 7.8.3.1. Key country dynamics
  - 7.8.3.2. Competitive scenario
  - 7.8.3.3. Regulatory framework
  - 7.8.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
- 7.8.4. UAE
  - 7.8.4.1. Key country dynamics
  - 7.8.4.2. Competitive scenario
  - 7.8.4.3. Regulatory framework
  - 7.8.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
- 7.8.5. Kuwait
  - 7.8.5.1. Key country dynamics
  - 7.8.5.2. Competitive scenario
  - 7.8.5.3. Regulatory framework
  - 7.8.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Company/Competition Categorization
8.2. Strategy Mapping
8.3. Company Market Position Analysis, 2025
8.4. Company Profiles/Listing
- 8.4.1. Bayer AG
  - 8.4.1.1. Company overview
  - 8.4.1.2. Financial performance
  - 8.4.1.3. Type benchmarking
  - 8.4.1.4. Strategic initiatives
- 8.4.2. Bio-Techne
  - 8.4.2.1. Company overview
  - 8.4.2.2. Financial performance
  - 8.4.2.3. Type benchmarking
  - 8.4.2.4. Strategic initiatives
- 8.4.3. BOC Sciences
  - 8.4.3.1. Company overview
  - 8.4.3.2. Financial performance
  - 8.4.3.3. Type benchmarking
  - 8.4.3.4. Strategic initiatives
- 8.4.4. BPS Bioscience, Inc.
  - 8.4.4.1. Company overview
  - 8.4.4.2. Financial performance
  - 8.4.4.3. Type benchmarking
  - 8.4.4.4. Strategic initiatives
- 8.4.5. BroadPharm
  - 8.4.5.1. Company overview
  - 8.4.5.2. Financial performance
  - 8.4.5.3. Type benchmarking
  - 8.4.5.4. Strategic initiatives
- 8.4.6. LifeSensors Inc.
  - 8.4.6.1. Company overview
  - 8.4.6.2. Financial performance
  - 8.4.6.3. Type benchmarking
  - 8.4.6.4. Strategic initiatives
- 8.4.7. MedChemExpress.
  - 8.4.7.1. Company overview
  - 8.4.7.2. Financial performance
  - 8.4.7.3. Type benchmarking
  - 8.4.7.4. Strategic initiatives
- 8.4.8. Merck KGaA
  - 8.4.8.1. Company overview
  - 8.4.8.2. Financial performance
  - 8.4.8.3. Type benchmarking
  - 8.4.8.4. Strategic initiatives
- 8.4.9. Promega Corporation
  - 8.4.9.1. Company overview
  - 8.4.9.2. Financial performance
  - 8.4.9.3. Type benchmarking
  - 8.4.9.4. Strategic initiatives
- 8.4.10. Thermo Fisher Scientific, Inc.
  - 8.4.10.1. Company overview
  - 8.4.10.2. Financial performance
  - 8.4.10.3. Type benchmarking
  - 8.4.10.4. Strategic initiatives

한글목차

표적 단백질 분해(TPD) 시장의 요약

목차

제1장 조사 방법과 범위

제2장 개요

제3장 표적 단백질 분해(TPD) 시장의 변수와 동향

제4장 표적 단백질 분해(TPD) 시장 : 유형별 추정·동향 분석

제5장 표적 단백질 분해(TPD) 시장 : 용도별 추정·동향 분석

제6장 표적 단백질 분해(TPD) 시장 : 최종 용도별 추정·동향 분석

제7장 표적 단백질 분해(TPD) 시장 : 지역별 추정·동향 분석

제8장 경쟁 구도